指南与共识浆细胞疾病

COVID-19大流行时期多发性骨髓瘤患者的管理:欧洲骨髓瘤网络(EMN)共识论文

Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN).
指南 / 共识 · Leukemia · 2020-05-22

欧洲骨髓瘤网络发布专家共识,指导COVID-19大流行期间多发性骨髓瘤(MM)患者的治疗决策。共识强调患者教育、治疗个体化、远程医疗和持续监测,并建议在SARS-CoV-2广泛传播地区入院、开始新治疗线、细胞采集或自体干细胞移植(ASCT)前进行鼻咽拭子PCR检测。口服方案可考虑用于老年虚弱标危患者,地塞米松、硼替佐米、卡非佐米和达雷妥尤单抗应基于风险与反应减量使用。

要点

  • MM患者因免疫抑制、高龄和合并症可能面临更严重COVID-19感染风险。
  • 在SARS-CoV-2广泛传播地区,入院、开始新治疗线、细胞采集或ASCT前应进行鼻咽拭子PCR检测。
  • 老年虚弱标危患者可考虑口服方案,地塞米松、硼替佐米、卡非佐米和达雷妥尤单抗应基于风险与反应减量。

核心结论

  • 欧洲骨髓瘤网络提供专家共识,指导COVID-19大流行期间MM患者的治疗决策。
  • 患者教育、治疗个体化、远程医疗和持续监测对早期诊断COVID-19至关重要。

研究设计与样本

  • 欧洲骨髓瘤网络(EMN)制定的专家共识文件。

主要发现

  • MM患者因免疫抑制状态、高龄和合并症可能面临更严重COVID-19感染及并发症风险。
  • 在COVID-19广泛传播的国家或社区,MM患者入院、开始新治疗线、细胞采集或ASCT前应进行鼻咽拭子SARS-CoV-2 PCR检测。
  • 老年虚弱标危患者可考虑口服药物方案,地塞米松、硼替佐米、卡非佐米和达雷妥尤单抗应基于患者风险和反应减量使用。
  • 对于有终末器官损害、骨髓瘤急症和侵袭性复发的患者,不应推迟治疗启动。
  • 自体(尤其是异基因)移植应延迟并延长诱导治疗,尤其适用于标危患者和诱导治疗反应充分的患者。

关键数值与推荐

  • 在COVID-19广泛传播地区,入院、开始新治疗线、细胞采集或ASCT前应进行鼻咽拭子SARS-CoV-2 PCR检测。
  • 老年虚弱标危患者可考虑口服药物方案。
  • 地塞米松、硼替佐米、卡非佐米和达雷妥尤单抗应基于患者风险和反应减量使用。
  • 有终末器官损害、骨髓瘤急症和侵袭性复发的患者不应推迟治疗启动。
  • 自体(尤其是异基因)移植应延迟并延长诱导治疗,尤其适用于标危患者和诱导反应充分者。

临床怎么用

  • 对MM患者进行个人卫生和社交距离教育,并实施治疗个体化、远程医疗和持续监测。
  • 在COVID-19广泛传播地区,入院、开始新治疗线、细胞采集或ASCT前进行鼻咽拭子SARS-CoV-2 PCR检测。
  • 老年虚弱标危患者可考虑口服药物方案,地塞米松、硼替佐米、卡非佐米和达雷妥尤单抗基于风险和反应减量。
  • 有终末器官损害、骨髓瘤急症和侵袭性复发的患者不应推迟治疗启动。
  • 自体(尤其是异基因)移植应延迟并延长诱导治疗,尤其适用于标危患者和诱导反应充分者。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with multiple myeloma (MM) seem to be at increased risk for more severe COVID-19 infection and associated complications due to their immunocompromised state, the older age and comorbidities. The European Myeloma Network has provided an expert consensus statement in order to guide therapeutic decisions in the era of the COVID-19 pandemic. Patient education for personal hygiene and social distancing measures, along with treatment individualization, telemedicine and continuous surveillance for early diagnosis of COVID-19 are essential. In countries or local communities where COVID-19 infection is widely spread, MM patients should have a PCR test of nasopharyngeal swab for SARS-CoV-2 before hospital admission, starting a new treatment line, cell apheresis or ASCT in order to avoid ward or community spread and infections. Oral agent-based regimens should be considered, especially for the elderly and frail patients with standard risk disease, whereas de-intensified regimens for dexamethasone, bortezomib, carfilzomib and daratumumab should be used based on patient risk and response. Treatment initiation should not be postponed for patients with end organ damage, myeloma emergencies and aggressive relapses. Autologous (and especially allogeneic) transplantation should be delayed and extended induction should be administered, especially in standard risk patients and those with adequate MM response to induction. Watchful waiting should be considered for standard risk relapsed patients with low tumor burden, and slow biochemical relapses. The conduction of clinical trials should continue with appropriate adaptations to the current circumstances. Patients with MM and symptomatic COVID-19 disease should interrupt anti-myeloma treatment until recovery. For patients with positive PCR test for SARS-CoV-2, but with no symptoms for COVID-19, a 14-day quarantine should be considered if myeloma-related events allow the delay of treatment. The need for surveillance for drug interactions due to polypharmacy is highlighted. The participation in international COVID-19 cancer registries is greatly encouraged.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Terpos E, Engelhardt M, Cook G, et al. Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN). Leukemia. 2020. PMID: 32444866. doi:10.1038/s41375-020-0876-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。